Toxicological Research

Korean Society of Toxicology & Korea Environmental Mutagen Society (한국독성학회)
권호 표지
DOI QR코드

DOI QR Code

A 6-Week Oral Toxicity Study of Oral Cholera Vaccine in Sprague-Dawley Rats

  • Received : 2012.07.05
  • Accepted : 2012.12.17
  • Published : 2012.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

The present study was carried out to examine the toxicity and target organs of oral cholera vaccine (OCV) after repeated oral administration in Sprague-Dawley rats for 6 weeks (3 administrations, once every 2 weeks). OCV is an inactivated oral cholera vaccine that contains Vibrio cholerae and confers protection against cholera caused by V. cholera serogroups O1 (Inaba and Ogawa serotypes) and O139 (strain 4260B). The animals were orally administered either OCV placebo (negative control) or OCV at a dose equivalent to 240 times the anticipated human dose. Throughout the administration period, no significant change was detected in clinical signs, body weight, food or water consumption, urinalysis results, hematological and clinical biochemistry test results, organ weights, necropsy, or histopathological examination results. Minor changes were found in hematological and clinical biochemistry tests; however, these changes were within normal ranges. The above results suggest that oral administration of OCV in rats did not induce any toxicologically meaningful changes, and the target organs could not be determined. This study was conducted in accordance with the guidelines established by Good Laboratory Practice (2009-183, KFDA, December 22, 2009) and the OECD Principles of Good Laboratory Practice (1997).

Keywords

References

  1. Clemens, J.D. (2011). Vaccines in the time of cholera. Proc. Natl. Acad. Sci. U.S.A., 108, 8529-8530. https://doi.org/10.1073/pnas.1105807108
  2. Deen, J.L., von Seidlein, L., Sur, D., Agtini, M., Lucas, M.E., Lopez, A.L., Kim, D.R., Ali, M. and Clemens, J.D. (2008). The high burden of cholera in children: comparison of incidence from endemic areas in Asia and Africa. PLoS Neglected Trop. Dis., 2, e173. https://doi.org/10.1371/journal.pntd.0000173
  3. Frerichs, R.R., Keim, P.S., Barrais, R. and Piarroux, R. (2012). Nepalese origin of cholera epidemic in Haiti. Clin. Microbiol. Infect., 18, E158-E163. https://doi.org/10.1111/j.1469-0691.2012.03841.x
  4. Greaves, P. (2000). Histopathology of preclinical toxicity studies: Interpretation and relevance in drug evaluation. Elsevier, Europe, pp. 1-892.
  5. Han, Z.Z., Xu, H.D., Kim, K.H., Ahn, T.H., Bae, J.S., Lee, J.Y., Gil, K.H., Lee, J.Y., Woo, S.J., Yoo, H.J., Lee, H.K., Kim, K.H., Park, C.K., Zhang, H.S. and Song, S.W. (2010). Referance data of the main physiological parameters in control Sprague-Dawley rats from pre-clinical toxicity studies. Lab. Anim. Res., 26, 153-164. https://doi.org/10.5625/lar.2010.26.2.153
  6. Harris, J.B., Larocque, R.C., Charles, R.C., Mazumder, R.N., Khan, A.I. and Bardhan, P.K. (2010). Cholera's western front. Lancet, 376, 1961-1965. https://doi.org/10.1016/S0140-6736(10)62172-1
  7. Klinger, M.M., MacCarter, G.D. and Boozer, C.N. (1996). Body weight and composition in the Sprague Dawley rat: comparison of three outbred sources. Lab. Anim. Sci., 46, 67-70.
  8. Lopez, A.L., Clemens, J.D., Deen, J. and Jodar, L. (2008). Cholera vaccines for the developing world. Hum. Vaccines, 4, 165-169. https://doi.org/10.4161/hv.4.2.5122
  9. Lucas, M.E., Jeuland, M., Deen, J., Lazaro, N., MacMahon, M., Nyamete, A., Barreto, A., von Seidlein, L., Cumbane, A., Songane, F.F. and Whittington, D. (2007). Private demand for cholera vaccines in Beira, Mozambique. Vaccine, 25, 2599-2609. https://doi.org/10.1016/j.vaccine.2006.12.027
  10. Morris, M. (1982). Neurohypophyseal response to dehydration in the spontaneously hypertensive rat. Hypertension, 4, 161-166. https://doi.org/10.1161/01.HYP.4.1.161
  11. Reiner, R.C. Jr., King, A.A., Emch, M., Yunus, M., Faruque, A.S. and Pascual, M. (2012). Highly localized sensitivity to climate forcing drives endemic cholera in a megacity. Proc. Natl. Acad. Sci. U.S.A., 109, 2033-2036. https://doi.org/10.1073/pnas.1108438109
  12. Sifontes-Rodriguez, S., Infante-Bourzac, J.F., Diaz-Rivero, D., Lopez-Feria, Y., Perez-Perez, M., Sosa-Roble, E., Perez-Amat, V., Lopez-Hernandez, Y., Alvarez-Figueredo, E., Martinez-Rodriguez, J.C., Farinas-Medina, M., Hernandez-Salazar, T., Tamayo-García, Y., Valdes-Abreu, Y., Ponce-Collera, A. and Rodriguez-Perez, N. (2009). Repeated dose toxicity study of a live attenuated oral cholera vaccine in Sprague Dawley rats. Arch. Med. Res., 40, 527-535. https://doi.org/10.1016/j.arcmed.2009.09.003
  13. Tacket, C.O., Cohen, M.B., Wasserman, S.S., Losonsky, G., Livio, S., Kotloff, K., Edelman, R., Kaper, J.B., Cryz, S.J., Giannella, R.A., Schiff, G. and Levine, M.M. (1999). Randomized, double- blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination. Infect. Immun., 67, 6341-6345.
  14. Trach, D.D., Clemens, J.D., Ke, N.T., Thuy, H.T., Son, N.D., Canh, D.G., Hang, P.V. and Rao, M.R. (1997). Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet, 349, 231-235. https://doi.org/10.1016/S0140-6736(96)06107-7
  15. World Heath Organization. (2004). Cholera vaccines: A new public health tool? Report of a meeting, Geneva, pp. 1-28.
  16. World Heath Organization. (2010). Weekly epidemiological record Releve epidemiologique hebdomadaire. W.H.O., 85, 293-308.
  17. Zuckerman, J.N., Rombo, L. and Fisch, A. (2007). The true burden and risk of cholera: implications for prevention and control. Lancet Infect. Dis., 7, 521-530. https://doi.org/10.1016/S1473-3099(07)70138-X

Cited by

  1. Maternal Nicotine Exposure During Late Gestation and Lactation Increases Anxiety-Like and Impulsive Decision-Making Behavior in Adolescent Offspring of Rat vol.32, pp.4, 2016, https://doi.org/10.5487/TR.2016.32.4.275